A new trading day began on Tuesday, with Autolus Therapeutics plc ADR (NASDAQ: AUTL) stock price down -2.71% from the previous day of trading, before settling in for the closing price of $2.95. AUTL’s price has ranged from $2.69 to $7.45 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 190.29% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 24.87%. With a float of $236.67 million, this company’s outstanding shares have now reached $266.12 million.
In an organization with 463 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 51.97%, operating margin of -1739.83%, and the pretax margin is -2172.6%.
Autolus Therapeutics plc ADR (AUTL) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Autolus Therapeutics plc ADR is 11.07%, while institutional ownership is 56.29%. The most recent insider transaction that took place on Sep 16 ’24, was worth 2,955,674.
Autolus Therapeutics plc ADR (AUTL) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 24.87% per share during the next fiscal year.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Trading Performance Indicators
Here are Autolus Therapeutics plc ADR’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 13.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 75.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.21, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach -0.78 in one year’s time.
Technical Analysis of Autolus Therapeutics plc ADR (AUTL)
Let’s dig in a bit further. During the last 5-days, its volume was 1.55 million. That was better than the volume of 1.47 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 12.48%. Additionally, its Average True Range was 0.24.
During the past 100 days, Autolus Therapeutics plc ADR’s (AUTL) raw stochastic average was set at 7.79%, which indicates a significant decrease from 23.68% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 51.31% in the past 14 days, which was lower than the 70.09% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.66, while its 200-day Moving Average is $4.23. However, in the short run, Autolus Therapeutics plc ADR’s stock first resistance to watch stands at $2.94. Second resistance stands at $3.01. The third major resistance level sits at $3.06. If the price goes on to break the first support level at $2.81, it is likely to go to the next support level at $2.76. The third support level lies at $2.69 if the price breaches the second support level.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Key Stats
With a market capitalization of 763.76 million, the company has a total of 266,094K Shares Outstanding. Currently, annual sales are 1,700 K while annual income is -208,380 K. The company’s previous quarter sales were 0 K while its latest quarter income was -58,270 K.
